Results 241 to 250 of about 14,398,598 (290)
Correction: Non-superagonist CD28-based dual-signal T cell engager targeting KK-LC-1 enhances antitumor efficacy. [PDF]
J Immunother Cancereuropepmc +1 more source
Journal of Hepatology, 2021 BACKGROUND & AIMS: Hepatitis B virus (HBV) infection is a global health threat responsible for 880,000 deaths per year. Current antiviral therapies control but rarely eliminate the virus, and leave chronic HBV carriers at risk to develop ...
Fazel Shokri +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
T-cell-engaging bispecific antibodies in cancer
The Lancet, 2023T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T cells to the tumour, followed by T-cell activation and degranulation, and tumour cell elimination.
Niels W C J, van de Donk +1 more
openaire +2 more sources
Molecular TherapyT cell-focused cancer immunotherapy including checkpoint inhibitors and cell therapies has been rapidly evolving over the past decade. Nevertheless, there remains a major unmet medical need in oncology generally and immuno-oncology specifically.
Akseli Hemminki, Anna Kanerva
exaly +2 more sources
T cell-engaging therapies — BiTEs and beyond
Nature Reviews Clinical Oncology, 2020Immuno-oncology approaches have entered clinical practice, with tremendous progress particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide an overview of the current status of bispecific T cell engager (BiTE) therapy, considering the unprecedented new indication for such therapy in combating minimal (or ...
Maria-Elisabeth Goebeler, Ralf C. Bargou
openaire +2 more sources
T-cell–engaging Therapy for Solid Tumors
Clinical Cancer Research, 2020Abstract T-cell engagers (TCE) are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T-cell surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptors or T-cell receptors, have similarities and ...
Maria de Miguel +4 more
openaire +2 more sources
Management of T-Cell Engaging Immunotherapy Complications
The Cancer Journal, 2019Abstract The advent of T-cell–mediated immunotherapy has led to a new era in the treatment of relapsed, refractory B-cell lymphomas and leukemias. Chimeric antigen receptor T-cell and engineered T-cell receptor therapies have demonstrated impressive efficacy in treating refractory disease.
Indumathy, Varadarajan, Daniel W, Lee
openaire +2 more sources
T-cell Engagers in Prostate Cancer
European UrologyOwing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 ...
Chadi, Hage Chehade +9 more
openaire +2 more sources
Bispecific T‐cell engagers for treatment of multiple myeloma
American Journal of Hematology, 2022AbstractBispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T‐cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B cell maturation antigen (BCMA) and differ among themselves ...
Gayathri Ravi, Luciano J. Costa
openaire +2 more sources